Genoil Inc. Files 6-K for Q1 2024

Ticker: GNOLF · Form: 6-K · Filed: May 28, 2024 · CIK: 1261002

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

Related Tickers: GNOLF

TL;DR

Genoil Inc. (GNOLF) filed its Q1 2024 6-K, confirming 20-F filing for annual reports.

AI Summary

Genoil Inc. filed a Form 6-K for the period ending March 31, 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under cover of Form 20-F. Genoil Inc. is incorporated in New York and its principal executive offices are located at One Rockefeller Plaza, 11th Floor, New York.

Why It Matters

This filing provides an update on Genoil Inc.'s reporting status as a foreign private issuer and its intention to file under Form 20-F, which is standard for companies with significant foreign operations or ownership.

Risk Assessment

Risk Level: low — This filing is a routine periodic report and does not contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report information that Genoil Inc. has made or is required to make public in Canada, filed or made public in the United States, or filed with the SEC, for the period ending March 31, 2024.

Which form will Genoil Inc. use for its annual reports?

Genoil Inc. will file its annual reports under cover of Form 20-F.

What is Genoil Inc.'s principal executive office address?

Genoil Inc.'s principal executive office is located at One Rockefeller Plaza, 11th Floor, New York.

What is the fiscal year end for Genoil Inc.?

Genoil Inc.'s fiscal year ends on December 31.

Is Genoil Inc. submitting this Form 6-K in paper format?

The filing indicates that Genoil Inc. is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).

Filing Stats: 384 words · 2 min read · ~1 pages · Grade level 15.5 · Accepted 2024-05-28 14:49:10

Filing Documents

Financial Statements

Financial Statements 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Genoil Inc. (Registrant) Date: May 28, 2024 By: /s/ David Lifschultz Name: David Lifschultz Title: CEO 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing